ARS Pharmaceuticals, Inc. (SPRY)
| Market Cap | 867.89M -39.6% |
| Revenue (ttm) | 84.28M -5.5% |
| Net Income | -171.30M |
| EPS | -1.74 |
| Shares Out | 99.30M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,271,936 |
| Open | 9.16 |
| Previous Close | 9.00 |
| Day's Range | 8.59 - 9.21 |
| 52-Week Range | 6.66 - 18.90 |
| Beta | 0.80 |
| Analysts | Strong Buy |
| Price Target | 40.00 (+357.67%) |
| Earnings Date | May 15, 2026 |
About SPRY
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for SPRY stock is "Strong Buy" and the 12-month stock price target is $40.0.
News
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patien...
ARS Pharmaceuticals announces Health Canada approval of neffy 2 mg
ARS Pharmaceuticals (SPRY) announced that Health Canada has granted approval for neffy 2 mg for the emergency treatment of allergic reactions in adults and children who weigh 30 kg or
neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
neffy offers a new delivery method for epinephrine in Canada for adults and children ( > 30 kg) living with severe allergic reactions
ARS Pharmaceuticals initiated with an Outperform at Northland
Northland initiated coverage of ARS Pharmaceuticals (SPRY) with an Outperform rating and $25 price target
Northland starts disruptor ARS Pharmaceuticals with an Outperform
As previously reported, Northland initiated coverage of ARS Pharmaceuticals (SPRY) with an Outperform rating and $25 price target Neffy is a needle-free intranasal epinephrine product that is disrupti...
ARS Pharmaceuticals receives FDA approval to remove neffy 1 mg age requirement
ARS Pharmaceuticals (SPRY) announced that the FDA has approved updating the neffy 1 mg prescribing information to remove the age criteria so all children and adults who weigh 33 pounds
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label
Children were previously required to weigh ≥33 lbs. and
ARS Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
Key goals include expanding neffy access to 90% coverage and advancing urticaria clinical trials, with strong pediatric uptake and high prescriber confidence. International launches, especially in Europe and China, are progressing well, and refill dynamics are expected to drive future growth.
ARS Pharmaceuticals Earnings Call Transcript: Q4 2025
2025 saw $84.3M in revenue and strong neffy adoption, with 93% commercial coverage and expanding DTC awareness. Sales force expansion and disciplined SG&A will support growth, while refill dynamics and broader access are expected to drive momentum in 2026.
ARS Pharmaceuticals reports Q4 EPS (42c), consensus (44c)
Reports Q4 revenue $28.1M, consensus $25.58M. “2025 was an important year for ARS Pharma as we established neffy as a differentiated, scalable epinephrine treatment of choice. We have built a
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization
neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million in ...
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences
SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patie...
ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
-Five poster presentations highlight clinical advancement of neffy , real-world usability and advantages of needle-free epinephrine delivery -Longer shelf life of nasal epinephrine compared with epin...
ARS Pharmaceuticals announces CHMP of EMA adopted positive opinion for EURneffy
ARS Pharmaceuticals (SPRY) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has adopted a positive opinion, recommending expanding the ma...
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to
EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma's partner, ALK-Abelló A/S, who owns the rights to market EURneffy in th...
ARS Pharmaceuticals announces California eligible for neffyinSchools program
ARS Pharmaceuticals (SPRY) announced that California is now eligible for its neffyinSchools program. “One year ago, we envisioned a nationwide program that would give school nurses and staff the confi...
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
California joins 23 other states eligible to receive free neffy ® (epinephrine nasal spray) at schools SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharm...
ARS Pharmaceuticals competitor gets FDA deficiency letter, says Raymond James
ARS Pharmaceuticals’ (SPRY) competitor Aquestive Therapeutics (AQST) received an FDA letter citing NDA deficiencies for Anaphylm, preventing discussion of labeling and post-marketing commitments, thou...
ARS Pharmaceuticals announces NMPA approval for neffy 2 mg
ARS Pharmaceuticals (SPRY) announced that the National Medical Products Administration in China has granted approval for neffy 2 mg for the emergency treatment of Type 1 allergic reactions in adults
neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)
neffy is the first epinephrine product approved for use out of a hospital setting in China for adults and children ( > 30 kg) living with severe allergic reactions Pediatrix Therapeutics, which has a ...
ARS Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference
Neffy adoption is accelerating, with over 20,000 prescribers and strong real-world data supporting its use. Access is expanding through payer coverage and the Get Neffy on Us program, while international launches are achieving premium pricing. Pipeline progress includes a lower-dose formulation for CSU.
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
SAN DIEGO, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect thems...
ARS Pharmaceuticals management to meet with Oppenheimer
Meeting to be held in New York on November 12-13 hosted by Oppenheimer.
ARS Pharmaceuticals price target lowered to $35 from $40 at Oppenheimer
Oppenheimer lowered the firm’s price target on ARS Pharmaceuticals (SPRY) to $35 from $40 and keeps an Outperform rating on the shares. The firm notes the company reported strong Q3
ARS Pharmaceuticals Earnings Call Transcript: Q3 2025
Q3 2025 saw U.S. neffy revenue surge 2.5x to $31.3M, exceeding expectations, with strong new patient growth and high refill intent. Strategic DTC campaigns and the Get neffy on Us program are driving adoption, while international launches and robust cash reserves support long-term growth.